Differential effects of medium- and long-chain saturated fatty acids on blood lipid profile: a systematic review and meta-analysis

2018 ◽  
Vol 108 (4) ◽  
pp. 675-687 ◽  
Author(s):  
Nisha Panth ◽  
Kylie A Abbott ◽  
Cintia B Dias ◽  
Katie Wynne ◽  
Manohar L Garg
Keyword(s):  
Fatty Acids ◽  
Blood Lipids ◽  
Ldl Cholesterol ◽  
Meta Analysis ◽  
Saturated Fatty Acids ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Weighted Mean ◽  
Lipids And Lipoproteins ◽  
Long Chain

Abstract Background Medium-chain saturated fatty acids (MCFAs) may affect circulating lipids and lipoproteins differently than long-chain saturated fatty acids (LCSFAs), but the results from human intervention trials have been equivocal. Objective The aim of this study was to determine whether MCFAs and LCSFAs have differential impacts on blood lipids and lipoproteins. Design Five databases were searched (EMBASE, MEDLINE, CINAHL, Cochrane, and Scopus) until April 2018, and published clinical trials investigating the differential effects of dietary MCFAs and LCSFAs on blood lipids were included. Searches were limited to the English language and to studies with adults aged >18 y. Where possible, studies were pooled for meta-analysis using RevMan 5.2. The principle summary measure was the mean difference between groups calculated using the random-effects model. Results Eleven eligible crossover and 1 parallel trial were identified with a total of 299 participants [weighted mean ± SD age: 38 ± 3 y; weighted mean ± SD body mass index (kg/m2): 24 ± 2]. All studies were pooled for the meta-analysis. Diets enriched with MCFAs led to significantly higher high-density lipoprotein (HDL) cholesterol concentrations than diets enriched with LCSFAs (0.11 mmol/L; 95% CI: 0.07, 0.15 mmol/L) with no effect on triglyceride, low-density lipoprotein (LDL) cholesterol, and total cholesterol concentrations. Consumption of diets rich in MCFAs significantly increased apolipoprotein A-I (apoA-I) concentrations compared with diets rich in LCSFAs (0.08 g/L; 95% CI: 0.02, 0.14 g/L). There was no evidence of statistical heterogeneity for HDL cholesterol, apoA-I, and triglyceride concentrations; however, significant heterogeneity was observed for the total cholesterol (I2 = 49%) and LDL cholesterol analysis (I2 = 58%). Conclusion The findings of this research demonstrate a differential effect of MCFAs and LCSFAs on HDL cholesterol concentrations. Further investigations are warranted to elucidate the mechanism by which the lipid profile is altered. This trial was registered at www.crd.york.ac.uk/PROSPERO as CRD42017078277.

Fat in animal products: facts and perceptions

1993 ◽  
Vol 17 ◽  
pp. 57-61 ◽  
Author(s):  
M. J. Gibney
Keyword(s):  
Fatty Acids ◽  
Dietary Fat ◽  
Ldl Cholesterol ◽  
Plasma Cholesterol ◽  
Saturated Fatty Acids ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Antioxidant Vitamins ◽  
Blood Cholesterol ◽  
Antioxidant Vitamin

AbstractEarly research in man at the end of the fifties and beginning of the sixties indicated that the composition of dietary fat influenced plasma cholesterol levels. In effect this research showed that plasma cholesterol was raised by saturated fatty acids (SFA), was lowered by polyunsaturated fatty acids (PUFA) and was not influenced by monounsaturated fatty acids (MUFA). Within the SFA it was also observed that the greater the chain length, the lesser the cholesterol raising effect. A quantitative relationship between the change in blood cholesterol (ΔC) resultant from changes in the percentage energy from SFA (ΔS) and PUFA (ΔP) was established as ΔC = 1.3 (2ΔS − ΔP). For the ensuing tivo decades this association dominated nutrition education programmes with the message that ‘saturates or animal fats raise blood cholesterol and polyunsaturates or vegetable oils lower blood cholesterol’.In the 1980s it became evident that the two main fractions of blood cholesterol yielded different risks for coronary heart disease. Low-density lipoprotein (LDL) cholesterol raised the risk and high-density lipoprotein (HDL) cholesterol lowered the risk. Earlier work on the qualitative effect of dietary fat was now repeated to examine the direction of change of the LDL and HDL subfractions of plasma cholesterol. Broadly speaking these data showed that SFA raised LDL cholesterol and had little effect on HDL cholesterol. PUFA lowered LDL cholesterol but when the intake was high, also lowered HDL cholesterol. Whilst this summarizes events leading up to current thinking on dietary fats and blood cholesterol, it is likely in the near future to be linked to another area of research involving the antioxidant vitamins and pro-vitamins (vitamin E, vitamin C and β-carotene). A growing body of data in the literature indicates a protective effect of antioxidant vitamins in epidemiological trials.Notwithstanding these findings, it is likely that dietary advice will continue to seek a lowering of SFA intake. PUFA intake will be capped and MUFA intake will be a more acceptable alternative. However, with increasing emphasis on antioxidant vitamin status, such advice is likely to be coupled with advice on increased consumption of fruit and vegetables.

Abstract MP66: Cheese Consumption and Blood Lipids; a Systematic Review and Meta-analysis of Randomized Controlled Trials

Circulation ◽  
2014 ◽  
Vol 129 (suppl_1) ◽  
Author(s):  
Janette de Goede ◽  
Johanna M Geleijnse ◽  
Eric L Ding ◽  
Sabita S. Soedamah-Muthu
Keyword(s):  
Total Cholesterol ◽  
Blood Lipids ◽  
Ldl Cholesterol ◽  
Meta Analysis ◽  
Hdl Cholesterol ◽  
Fat Content ◽  
Control Treatment ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Lipids And Lipoproteins

Aims: Cheese may have a different effect on lipids and lipoproteins than expected from the saturated fat content. We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) to examine the effect of cheese consumption on blood lipids and lipoproteins in healthy populations. Methods: A systematic search in MEDLINE, EMBASE, Scopus, Cababstracts, Cochrane Controlled Trials Register, Clinicaltrials.gov was performed to identify RCTs of cheese supplementation in human adults with total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides as a primary or secondary outcome (published until September 2013). A quantitative meta-analysis was performed if more than four RCTs with a comparable control treatment were available. Within person-differences of lipids with corresponding standard errors caused by the cheese compared to the control treatment were pooled (random effects model, STATA 11.0). Results: We identified 15 RCTs, published between 1978 and 2012. We pooled four RCTs comparing the effect of cheese intake to butter with a similar fat content on plasma levels of total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides. The amount of cheese used in these trials was rather large, ranging between 120 and 205 g/d. This is approximately equivalent to 3 to 5 cheese servings per day. Intake of cheese (weighted mean difference: 142.6 g/d) reduced total cholesterol significantly by -0.27 mmol/l (95% CI: -0.36 to -0.18), LDL-C by -0.21 mmol/l (95% CI: -0.29 to -0.13), and HDL-C by -0.05 (95% CI: -0.08 to -0.02) compared to butter. The pooled effect on triglycerides was 0.004 (95% CI: -0.058 to 0.065). No heterogeneity was observed (all I 2 =0%). Cheese was also compared with tofu (n=4 RCTs), fat-modified cheese (n=3), CLA-rich cheese (n=3), milk (n=2), fish (n=1), egg white (n=1). Trials that compared cheese with tofu or fat-modified cheese suggest that differential effects of the products can mainly be attributed to the differences in fatty acid content of the diets. Comparisons with CLA-rich cheese were of limited value because those studied the effects of CLA (and not cheese). Too few trials with milk, egg white, and fish were available to draw conclusions. Conclusions: Based on a limited number of trials, cheese appears less hypercholesterolemic than butter with a similar fat content. Differences in plasma lipids based on cheese compared with tofu and fat-modified products are likely to be caused by the different fat content of the total diets.

scholarly journals Effect of green tea consumption on blood lipids: a systematic review and meta-analysis of randomized controlled trials

2020 ◽  
Vol 19 (1) ◽  
Author(s):  
Renfan Xu ◽  
Ke Yang ◽  
Sui Li ◽  
Meiyan Dai ◽  
Guangzhi Chen
Keyword(s):  
Publication Bias ◽  
Green Tea ◽  
Blood Lipids ◽  
Ldl Cholesterol ◽  
Meta Analysis ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Tea Consumption ◽  
Randomized Controlled ◽  
Funnel Plots

Abstract Background Strong epidemiologic evidence indicates that green tea intake is protective against hyperlipidemia; however, randomized controlled studies have presented varying results. In the present study, we aimed to conduct a literature review and meta-analysis to assess the effect of green tea on blood lipids. Methods PubMed, Embase, and the Cochrane Library were electronically explored from inception to September 2019 for all relevant studies. Random effect models were used to estimate blood lipid changes between green tea supplementation and control groups by evaluating the weighted mean differences (WMD) with 95% confidence intervals (CIs). The risk of bias for study was assessed using the Cochrane tool. Publication bias was evaluated using funnel plots and Egger’s tests. Results Thirty-one trials with a total of 3321 subjects were included in the meta-analysis. In general, green tea intake significantly lowered the total cholesterol (TC); WMD: − 4.66 mg/dL; 95% CI: − 6.36, − 2.96 mg/dL; P < 0.0001) and low-density lipoprotein (LDL) cholesterol (WMD:− 4.55 mg/dL; 95% CI: − 6.31, − 2.80 mg/dL; P < 0.0001) levels compared with those in the control. Green tea consumption did not affect high-density lipoprotein (HDL) cholesterol; however, it reduced the triglycerides compared with that in the control (WMD: − 3.77 mg/dL; 95% CI: − 8.90, 1.37 mg/dL; P = 0.15). In addition, significant publication bias from funnel plots or Egger’s tests was not evident. Conclusions Collectively, consumption of green tea lowers LDL cholesterol and TC, but not HDL cholesterol or triglycerides in both normal weight subjects and those who were overweight/obese; however, additional well-designed studies that include more diverse populations and longer duration are warranted.

scholarly journals Increased serum cholesterol and long-chain fatty acid levels are associated with the efficacy of nivolumab in patients with non-small cell lung cancer

2021 ◽  
Author(s):  
Masato Karayama ◽  
Naoki Inui ◽  
Yusuke Inoue ◽  
Katsuhiro Yoshimura ◽  
Kazutaka Mori ◽  
...  
Keyword(s):  
Serum Cholesterol ◽  
Serum Lipid ◽  
Ldl Cholesterol ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Small Cell ◽  
Chain Fatty Acid ◽  
Small Cell Lung ◽  
Long Chain Fatty Acid ◽  
Long Chain

Abstract Background Lipids have immunomodulatory functions and the potential to affect cancer immunity. Methods The associations of pretreatment serum cholesterol and long-chain fatty acids with the objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were evaluated in 148 patients with non-small cell lung cancer who received nivolumab. Results When each lipid was separately evaluated, increased low-density lipoprotein (LDL)-cholesterol (P < 0.001), high-density lipoprotein (HDL)-cholesterol (P = 0.014), total cholesterol (P = 0.007), lauric acid (P = 0.015), myristic acid (P = 0.022), myristoleic acid (P = 0.035), stearic acid (P = 0.028), linoleic acid (P = 0.005), arachidic acid (P = 0.027), eicosadienoic acid (P = 0.017), dihomo-γ-linolenic acid (P = 0.036), and behenic acid levels (P = 0.032) were associated with longer PFS independent of programmed death ligand 1 (PD-L1) expression. Meanwhile, increased LDL-cholesterol (P < 0.001), HDL-cholesterol (P = 0.009), total cholesterol (P = 0.036), linoleic acid (P = 0.014), and lignoceric acid levels (P = 0.028) were associated with longer OS independent of PD-L1 expression. When multiple lipids were evaluated simultaneously, LDL-cholesterol (P = 0.003), HDL-cholesterol (P = 0.036), and lauric acid (P = 0.036) were independently predictive of PFS, and LDL-cholesterol (P = 0.008) and HDL-cholesterol (P = 0.031) were predictive of OS. ORR was not associated with any serum lipid. Conclusions Based on the association of prolonged survival in patients with increased serum cholesterol and long-chain fatty acid levels, serum lipid levels may be useful for predicting the efficacy of immune checkpoint inhibitor therapy.

Abstract MP014: Very Long Chain Saturated Fatty Acids and Diabetes Risk: Meta-Analysis of Cohort Studies in the FORCE Consortium

Circulation ◽  
2017 ◽  
Vol 135 (suppl_1) ◽  
Author(s):  
Amanda Fretts ◽  
Fumiaki Imamura ◽  
Chaoyu Yu ◽  
Alexis C Frazier-Wood ◽  
Maria Lankinen ◽  
...  
Keyword(s):  
Fatty Acids ◽  
Palmitic Acid ◽  
Lower Risk ◽  
Fixed Effects ◽  
Meta Analysis ◽  
Arachidic Acid ◽  
Saturated Fatty Acids ◽  
Diabetes Risk ◽  
Incident Diabetes ◽  
Long Chain

Background: Circulating saturated fatty acids are biomarkers of diet and metabolism that may influence the pathogenesis of diabetes. Unlike palmitic acid (16:0), which has been extensively studied, little is known of the relationship of very long-chain saturated fatty acids (VLSFAs), with 20 carbons or more, to diabetes risk. Objective: To investigate the associations of circulating levels of VLSFA with incident diabetes. Methods: A meta-analysis was conducted within a consortium of prospective (cohort or nested case-control) studies having circulating measures of one or more VLSFAs, including arachidic acid (20:0), behenic acid (22:0) and lignoceric acid (24:0). Standardized analysis was conducted in each study using pre-specified models, exposures, outcomes, and covariates. Study-specific estimates were pooled using fixed effects meta-analysis. Results: Current findings were based on 9 participating studies, including 46,549 total participants and 13,750 incident diabetes. In multivariable-adjusted analyses, higher levels of all 3 VLSFAs were associated with lower risk of incident diabetes. Pooled RRs (95% CI) per interquintile range were 0.80 (0.71-0.90) for 20:0; 0.83 (0.76-0.91) for 22:0; and 0.70 (0.63-0.79) for 24:0, after adjustment for demographics, lifestyle factors and clinical conditions. Additional adjustments for circulating palmitic acid and triglyceride levels moved the RRs toward the null (illustrated for 24:0, in model 3 of the Figure ). Conclusions: Based on meta-analysis of results from several studies around the world, biomarker levels of VLSFA are associated with lower risk of incident diabetes, potentially mediated by effects on circulating triglycerides and 16:0.

Oral administration of D-003, a mixture of very long chain fatty acids prevents casein-induced endogenous hypercholesterolemia in rabbits

2004 ◽  
Vol 82 (1) ◽  
pp. 22-29 ◽  
Author(s):  
R Menéndez ◽  
R Más ◽  
J Pérez ◽  
R M González ◽  
S Jiménez
Keyword(s):  
Fatty Acids ◽  
De Novo ◽  
Reductase Activity ◽  
Cholesterol Biosynthesis ◽  
Saturated Fatty Acids ◽  
Density Lipoprotein ◽  
Cholesterol Absorption ◽  
Cholesterol Concentration ◽  
Proximal Small Bowel ◽  
Long Chain

D-003 is a mixture of very long chain saturated fatty acids (VLCSFA) purified from sugar cane wax with cholesterol-lowering effects proven in animal models and healthy volunteers. D-003 inhibits cholesterol biosynthesis through the regulation of HMG-CoA reductase activity. Rabbits fed diets enriched with casein develop endogenous hypercholesterolemia (EH), making them a very useful model for determining the mechanism of action of drugs affecting lipids. We examined whether D-003 prevented EH. Rabbits were fed a casein diet for 4 weeks, administered simultaneously with D-003 (5, 50, and 100 mg·kg–1·day–1). As expected, nontreated rabbits became hipercholesterolemic; however, as early as 15 days following administration, the treated group (50 and 100 mg·kg–1·day–1) had significantly decreased total cholesterol and low-density lipoprotein cholesterol (LDL-C). Triglycerides were not affected; however, at study completion, HDL-C levels significantly increased at all the doses assayed. D-003 inhibited de novo synthesis of cholesterol, since the incorporation of 3H2O into sterols in the liver and proximal small bowel was significantly depressed. Also, D-003 significantly raised the rate of removal of [125I]-LDL from serum and significantly elevated [125I]-LDL binding activity to liver homogenates. Taken together, these results show that the efficacy of D-003 in reducing casein-derived hypercholesteromeia could involve, at least partially, an inhibition of hepatic cholesterol bio synthesis, which may elicit a decreased cholesterol concentration in hepatocytes, preventing the loss of hepatic LDL receptors induced by casein administration. However, since casein-induced hypercholesterolemia is also a consequence of a stimulation of cholesterol absorption in the lumen and an increase of the output of cholesterol associated with LDL, the effect of D-003 on cholesterol absorption and LDL synthesis by the liver should be investigated.Key words: D-003, very long chain saturated fatty acids, casein-fed rabbits, LDL-C, cholesterol biosynthesis, LDL clearance, LDL receptor.

scholarly journals EFFECTS OF VITAMIN B12 ON SERUM LIPIDS AND LIPOPROTEINS OF PIGS FED DIETS SUPPLEMENTED WITH PROPIONIC ACID OR CALCIUM PROPIONATE

1982 ◽  
Vol 62 (2) ◽  
pp. 527-536 ◽  
Author(s):  
P.A. THACKER ◽  
J.P. BOWLAND ◽  
M. FENTON
Keyword(s):  
Propionic Acid ◽  
Feed Intake ◽  
Serum Lipids ◽  
Ldl Cholesterol ◽  
Cholesterol Metabolism ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Vitamin B ◽  
Calcium Propionate ◽  
Lipids And Lipoproteins

Effects of vitamin B12 supplementation of diets containing propionic acid (PA), or calcium propionate (CP) on feed intake, serum lipids and lipoproteins were studied utilizing 80 crossbred pigs averaging 22.5 kg. Diets, based on barley-soybean meal, containing 0, 3.5 or 7% PA or CP, were fed with and without the addition of 4.95 mg vitamin B12/kg diet. Inclusion of PA or CP with or without the addition of vitamin B12 had no significant effect on feed intake. Addition of PA or CP depressed serum cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol and serum triglycerides. Vitamin B12 supplementation had no effect on serum total cholesterol or HDL cholesterol, caused a reduction in LDL cholesterol, and tended to overcome the reduction in serum triglyceride. Supplementation of diets with vitamin B12 reduced liver lipid levels, largely as a result of a decrease in cholesterol and phospholipids. These data suggest that the cholesterol-lowering effect of PA is not simply a result of a depression in feed intake, but arises from a direct action of PA on cholesterol metabolism. Key words: Vitamin B12, lipids, lipo protein, pigs, propionic, propionate

scholarly journals Meta-regression analysis of the effects of dietary cholesterol intake on LDL and HDL cholesterol

2018 ◽  
Vol 109 (1) ◽  
pp. 7-16 ◽  
Author(s):  
Melissa J Vincent ◽  
Bruce Allen ◽  
Orsolya M Palacios ◽  
Lynne T Haber ◽  
Kevin C Maki
Keyword(s):  
Cardiovascular Disease ◽  
Fatty Acids ◽  
Regression Analysis ◽  
Ldl Cholesterol ◽  
Dietary Cholesterol ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Cholesterol Intake ◽  
Meta Regression ◽  
Meta Regression Analysis

ABSTRACTBackgroundElevated low-density lipoprotein (LDL) cholesterol is a major risk factor for cardiovascular disease. Dietary guidance recommends reducing saturated fatty acid, trans fatty acid, and cholesterol intakes to reduce circulating LDL cholesterol. Cholesterol intake may also affect high-density lipoprotein (HDL)–cholesterol concentrations, but its impact has not been fully quantified.ObjectivesThe aims of this study were to investigate the dose-response relation between changes in dietary cholesterol intake and changes in lipoprotein-cholesterol markers for cardiovascular disease risk and to provide a reference for clinicians on how changes in dietary cholesterol intake affect circulating cholesterol concentrations, after accounting for intakes of fatty acids.MethodsWe used a Bayesian approach to meta-regression analysis, which uses Markov chain Monte Carlo techniques, to assess the relation between the change in dietary cholesterol (adjusted for dietary fatty acids) and changes in LDL and HDL cholesterol based on the use of data from randomized dietary intervention trials.ResultsFifty-five studies (2652 subjects) were included in the analysis. The nonlinear Michaelis-Menten (MM) and Hill models best described the data across the full spectrum of dietary cholesterol changes studied (0–1500 mg/d). Mean predicted changes in LDL cholesterol for an increase of 100 mg dietary cholesterol/d were 1.90, 4.46, and 4.58 mg/dL for the linear, nonlinear MM, and Hill models, respectively.ConclusionsThe change in dietary cholesterol was positively associated with the change in LDL-cholesterol concentration. The linear and MM models indicate that the change in dietary cholesterol is modestly inversely related to the change in circulating HDL-cholesterol concentrations in men but is positively related in women. The clinical implications of HDL-cholesterol changes associated with dietary cholesterol remain uncertain.

Short Communication: Effects of duodenal infusion of increasing amounts of α-linolenic acid on composition and susceptibility to peroxidation of blood lipids in lactating dairy cows

2012 ◽  
Vol 92 (2) ◽  
pp. 219-223 ◽  
Author(s):  
Peng Sun ◽  
Jia-Qi Wang ◽  
Qing-Sheng Liu ◽  
Khas-Erdene ◽  
Guang Yang
Keyword(s):  
Fatty Acids ◽  
Dairy Cows ◽  
Linolenic Acid ◽  
Blood Lipids ◽  
Short Communication ◽  
Saturated Fatty Acids ◽  
Density Lipoprotein ◽  
Thiobarbituric Acid ◽  
Lactating Dairy Cows ◽  
Communication Effects

Sun, P., Wang, J.-Q., Liu, Q.-S., Khas-Erdene and Yang, G. 2012. Short Communication: Effects of duodenal infusion of increasing amounts of α-linolenic acid on composition and susceptibility to peroxidation of blood lipids in lactating dairy cows. Can. J. Anim. Sci. 92: 219–223. Duodenal infusion of increasing amounts of α-linolenic acid (LNA) in dairy cows linearly decreased the percentages of 18:0, 18:2n-6 and saturated fatty acids (P<0.01), linearly and quadratically reduced 23:0 and 18:1 cis-9 (P<0.01), but linearly increased the content of 18:3 n-3 and PUFA (P<0.01) in blood plasma. As amount infused increased, concentrations of high-density lipoprotein cholesterol and total cholesterol increased quadratically and peaked at 139.9 mg dL−1 and 182.0 mg dL−1, respectively (P<0.01). No differences were observed in the activity of blood serum total superoxide dismutase and total antioxidant capacity, but the thiobarbituric acid reactive substances tended (P=0.07) to increase linearly. Duodenally infused increasing amounts of LNA altered the composition of fatty acids and distribution of lipids in blood, but did not affect the oxidative stability of the blood in dairy cows.

scholarly journals A Non-Probiotic Fermented Soy Product Reduces Total and LDL Cholesterol: A Randomized Controlled Crossover Trial

Nutrients ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 535
Author(s):  
Sarah M. Jung ◽  
Ella H. Haddad ◽  
Amandeep Kaur ◽  
Rawiwan Sirirat ◽  
Alice Y. Kim ◽  
...  
Keyword(s):  
Blood Lipids ◽  
Ldl Cholesterol ◽  
Disease Risk ◽  
Cardiovascular Disease Risk ◽  
Brown Rice ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Apolipoprotein A1 ◽  
Germinated Brown Rice ◽  
Randomized Controlled

Traditional Asian fermented soy food products are associated with reduced cardiovascular disease risk in prospective studies, but few randomized controlled trials have been conducted in at-risk populations. The aim of this study was to investigate the effect of a commercial non-probiotic fermented soy product on blood lipids in adults with cardiovascular risk biomarkers. In a randomized, crossover, intervention study, 27 men and women (aged 29–75 y) exhibiting at least two risk factors, consumed two packets (12.5 g each) daily of a fermented powdered soy product, or an isoenergic control powder made from germinated brown rice for 12 weeks each. The consumption of the fermented soy product resulted in a significantly greater mean change from baseline (compared to the germinated rice, all p < 0.05) in total cholesterol of −0.23 mmol/L (CI: −0.40, −0.06) compared with 0.14 mmol/L (CI: −0.03, 0.31), respectively; and low density lipoprotein (LDL) cholesterol −0.18 mmol/L (CI: −0.32, −0.04) compared with 0.04 mmol/L (CI: −0.01, 0.018) respectively. This was accompanied by an increase in high density lipoprotein (HDL) cholesterol in the germinated rice group, a decrease in apolipoprotein B (ApoB) in the fermented soy group, and a between-treatment effect in apolipoprotein A1 (ApoA1); however, the ratio of the LDL:HDL and of Apo B:ApoA1 did not differ between the groups. The ratio of total cholesterol:LDL decreased in men in the fermented soy group (p < 0.001). Twenty-four-hour urine collection at the end of each treatment period resulted in an increased excretion expressed as a ratio in μmol/d between treatments of 10.93 (CI: 5.07, 23.54) for daidzein; 1.24 (CI: 1.14, 4.43) for genistein; and, 8.48 (CI: 4.28, 16.80) for glycitein, all p < 0.05. The fermented soy powder consumed by participants in this study without implementing other changes in their typical diets, decreased the total and LDL cholesterol, and may serve as a dietary strategy to manage blood lipids. The trial was registered at ClinicalTrials.gov as NCT03429920.

Sign in / Sign up

Export Citation Format

Share Document